A new class of diabetes drugs called SGLT-2 inhibitors -- which block the natural reabsorption of excess glucose in the bloodstream and allow it to pass out of the body -- could potentially be huge in the type 2 diabetes space, and Johnson & Johnson (NYSE:JNJ) recently received a 10-5 recommendation for approval for its SGLT-2 inhibitor Invokana from an FDA advisory committee. If approved, JNJ would be the first to market in the United States with this type of drug, which could be a nice win for the company.
Brenton Flynn has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.